Molecular techniques in cytopathology practice

Journal of Clinical Pathology

Volumn 61, Issue 3, 2008, Pages 258-267

  Schmitt, Fernando Carlos ^a,b,f   Longatto Filho, A ^c,d   Valent, A ^e   Vielh, P ^e  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

^c UNIVERSITY OF MINHO   (Portugal)

^d INSTITUTO ADOLFO LUTZ   (Brazil)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f NONE   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; LAPATINIB; ONCOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN; RNA; TRANSCRIPTION FACTOR PAX8; TRASTUZUMAB; TUMOR SUPPRESSOR PROTEIN; ZINC FINGER PROTEIN;

ASPIRATION BIOPSY; ASPIRATION CYTOLOGY; BREAST CANCER; CANCER DIAGNOSIS; CANCER GENETICS; CANCER INVASION; CHROMOGENIC IN SITU HYBRIDIZATION; CHROMOSOME TRANSLOCATION; COLPOSCOPY; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOPATHOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DNA DETERMINATION; EFFUSION; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE MUTATION; GENE REARRANGEMENT; GENETIC ALGORITHM; GYNECOLOGICAL EXAMINATION; HETEROZYGOSITY LOSS; HIGH RISK PATIENT; HUMAN; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION; INFECTION RISK; INTERMETHOD COMPARISON; INVASIVE CARCINOMA; LABORATORY TEST; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT TRANSFORMATION; MEDICAL TECHNOLOGY; MOLECULAR BIOLOGY; ONCOGENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA ANALYSIS; SARCOMA; SEROSA; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; SQUAMOUS CELL CARCINOMA; T CELL LYMPHOMA; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; URINE CYTOLOGY; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

CYTOGENETIC ANALYSIS; DNA; DNA, VIRAL; FEMALE; FORECASTING; GENE REARRANGEMENT; GENITAL DISEASES, FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG DISEASES; MALE; PAPILLOMAVIRUS INFECTIONS; THYROID DISEASES; VAGINAL SMEARS;

EID: 40449138653     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2006.044347     Document Type: Review

References (74)

1. Akerman M, Alves VA, Bubendorf L, et al. How technology is reshaping the practice of nongynecologic cytology. Acta Cytol 2007;51:123-52.
2. Reis-Filho JS, Schmitt FC. Fluorescence in situ hybridization, comparative genomic hybridization, and other molecular biology techniques in the analysis of effusions. Diagn Cytopathol 2005;33:294-9.
3. Rapkiewicz A, Espina V, Zujewski JA, et al. The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology. Cancer 2007;111:173-84.
4. Nonogaki S, Wakamatsu A, Longatto Filho A, et al. Molecular strategies for identifying human papillomavirus infection in routinely processed samples: focus on paraffin sections. J Low Genit Tract Dis 2005;9:219-24.
5. Coste J, Cochand-Priollet B, de Crémoux P, et al. Cross sectional study of conventional cervical smear, monolayer cytology and human papillomavirus DNA testing for cervical cancer screening. BMJ 2003;326:733-7.
6. Ronco G, Cuzick J, Pierotti P, et al. Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening randomised controlled trial. BMJ 2007;335:28.
7. Longatto-Filho A, Maeda MY, Erzen M, et al. Conventional Pap smear and liquid-based cytology as screening tools in low-resource settings in Latin America: experience of the Latin American screening study. Acta Cytol 2005;49:500-6.
8. Longatto Filho A, Pereira SM, Di Loreto C, et al. DCS liquid-based system is more effective than conventional smears to diagnosis of cervical lesions: study in high-risk population with biopsy-based confirmation. Gynecol Oncol 2005;97:497-500.
9. de Crémoux P, Coste J, Sastre-Gareau X, et al. Efficiency of the hybrid capture 2 HPV test in cervical cancer screening. A study by the French Society of Clinical Cytology. Am J Clin Pathol 2003;120:492-9.
10. Taha NS, Focchi J, Ribalta JC, et al. Universal Collection Medium (UCM) is as suitable as the Standard Transport Medium (STM) for hybrid capture II (HC-2) assay. J Clin Virol 2006;36:32-5.
11. Nonogaki S, Wakamatsu A, Longatto Filho A, et al. Hybrid capture II and polymerase chain reaction for identifying HPV infections in samples collected in a new collection medium: a comparison. Acta Cytol 2004;48:514-20.
12. Habis AH, Vernon SD, Lee DR, et al. Molecular quality of exfoliated cervical cells: implications for molecular epidemiology and biomarker discovery. Cancer Epidemiol Biomarkers Prev 2004;13:492-6.
13. Steinau M, Lee DR, Rajeevan MS, et al. Gene expression profile of cervical tissue compared to exfoliated cells: impact on biomarker discovery. BMC Genomics 2005;6:64.
14. Castle PE, Solomon D, Hildesheim A, et al. Stability of archived liquid-based cervical cytologic specimens. Cancer 2003;99:89-96.
15. Wright TC Jr. Cervical cancer screening in the 21st century: is it time to retire the PAP smear? Clin Obstet Gynecol 2007;50:313-23.
16. Franco EL, Cuzick J, Hildesheim A, et al. Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 2006;24(Suppl 3):S171-7.
17. Kohli M, Ferko N, Martin A, et al. Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. Br J Cancer 2007;96:143-50.
18. Petignat P, Faltin DL, Bruchim I, et al. Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis. Gynecol Oncol 2007;105:530-5.
19. Akhras MS, Thiyagarajan S, Villabianca AC, et al. PathogenMip assay: a multiplex pathogen detection assay. PLoS ONE 2007;2:e223.
20. von Knebel-Doeberitz M, Syrjanen KJ. Molecular markers: how to apply in practice. Gynecol Oncol 2006;103:18-20.
21. Longatto Filho A, Utagawa ML, Shirata NK, et al. Immunocytochemical expression of p16INK4A and Ki-67 in cytologically negative and equivocal pap smears positive for oncogenic human papillomavirus. Int J Gynecol Pathol 2005;24:118-24.
22. Murphy N, Ring M, Killalea AG, et al. p16INK4A as a marker for cervical dyskaryosis: CIN and cGIN in cervical biopsies and ThinPrep smears. J Clin Pathol 2003;56:56-63.
23. ink4a and fragile histidine triad (fhit) gene expression and cervical lesions. J Low Genit Tract Dis 2007;11:151-7.
24. Hidalgo A, Baudis M, Petersen I, et al. Microarray comparative genomic hybridization detection of chromosomal imbalances in uterine cervix carcinoma. BMC Cancer 2005;5:77.
25. Longatto Filho A, Albergaria A, Paredes J, et al. P-cadherin expression in glandular lesions of the uterine cervix detected by liquid-based cytology. Cytopathology 2005;16:88-93.
26. Feng Q, Balasubramanian A, Hawes SE, et al. Detection of hypermethylated genes in women with and without cervical neoplasia. J Natl Cancer Inst 2005;97:273-82.
27. Kloth JN, Oosting J, van Wezel T, et al. Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex genetic alterations in cervical cancer. BMC Genomics 2007;20:53.
28. Pereira TC, Saad RS, Liu Y, et al. The diagnosis of malignancy in effusion cytology: a pattern recognition approach. Adv Anat Pathol 2006;13:174-84.
29. Zhu W, Michael CW. WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions. Diagn Cytopathol 2007;35:370-5.
30. Granja NM, Begnami MD, Bortolan J, et al. Desmoplastic small round cell tumour: cytological and immunocytochemical features. Cytojournal 2005;2:6.
31. Longatto Filho A, Alves VA, Kanamura CT, et al. Identification of the primary site of metastatic adenocarcinoma in serous effusions. Value of an immunocytochemical panel added to the clinical arsenal. Acta Cytol 2002;46:651-8.
32. Granja NM, Ricardo SA, Longatto Filho A, et al. Potential use of loss of heterozygosity in pleural effusions of breast cancer metastases using the microsatellite marker of the 16q22.1 region of the CDH1 gene. Anal Quant Cytol Histol 2005;27:61-6.
33. de Matos Granja N, Soares R, Rocha S, et al. Evaluation of breast cancer metastases in pleural effusions by molecular biology techniques. Diagn Cytopathol 2002;27:210-3.
34. Das DK. Serous effusions in malignant lymphomas: a review. Diagn Cytopathol 2006;34:335-47.
35. Santos GC, Longatto-Filho A, de Carvalho LV, et al. Immunocytochemical study of malignant lymphoma in serous effusions. Acta Cytol 2000;44:539-42.
36. Kaleem Z. Flow cytometric analysis of lymphomas: current status and usefulness. Arch Pathol Lab Med 2006;130:1850-8.
37. Fiegl M, Massoner A, Haun M, et al. Sensitive detection of tumour cells in effusions by combining cytology and fluorescence in situ hybridisation (FISH). Br J Cancer 2004;91:558-63.
38. Nagel H, Schulten HJ, Gunawan B, et al. The potential value of comparative genomic hybridization analysis in effusion and fine needle aspiration cytology. Mod Pathol 2002;15:818-25.
39. Yen CC, Liang SC, Jong YJ, et al. Chromosomal aberrations of malignant pleural effusions of lung adenocarcinoma: different cytogenetic changes are correlated with genders and smoking habits. Lung Cancer 2007;57:292-301.
40. Shu J, Sun GY, Liu AP, et al. Diagnostic accuracy of human telomerase reverse transcriptase mRNA in malignant pleural effusions: a preliminary report for in situ hybridization detection. Clin Chim Acta 2007;381:131-5.
41. Li G, Passebosc-Faure K, Feng G, et al. MN/CA9: a potential gene marker for detection of malignant cells in effusions. Biomarkers 2007;12:214-20.
42. Passebosc-Faure K, Li G, Lambert C, et al. Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions. Clin Cancer Pes 2005;11 (19 Pt 1):6862-7.
43. Fiegl M, Haun M, Massoner A, et al. Combination of cytology, fluorescence in situ hybridization for aneuploidy, and reverse-transcriptase polymerase chain reaction for human mammaglobin/ mammaglobin B expression improves diagnosis of malignant effusions. J Clin Oncol 2004;22:474-83.
44. Davidson B, Berner A, Trope CG, et al. Expression and clinical role of the bric-a-brac tramtrack broad complex/poxvirus and zinc protein NAC-1 in ovarian carcinoma effusions. Hum Pathol 2007;38:1030-6.
45. Kleinberg L, Lie AK, Florenes VA, et al. Expression of inhibitor-of-apoptosis protein family members in malignant mesothelioma. Hum Pathol 2007;38:986-94.
46. Junker K, Fritsch T, Hartmann A, et al. Multicolor fluorescence in situ hybridization (M-FISH) on cells from urine for the detection of bladder cancer. Cytogenet Genome Res 2006;114:279-83.
47. Skacel M, Fahmy M, Brainard JA, et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 2003;169:2101-5.
48. Zellweger T, Benz G, Cathomas G, et al. Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer. Int J Cancer 2006;119:1660-5.
49. Li R, Liu Z, Fan T, et al. A novel multiple FISH array for the detection of genetic aberrations in cancer. Lab Invest 2006;86:619-27.
50. Halling KC, Rickman OB, Kipp BR, et al. A comparison of cytology and fluorescence in situ hybridization for the detection of lung cancer in bronchoscope specimens. Chest 2006;13:694-701.
51. Kettunen E, Salmenkivi K, Vuopala K, et al. Copy number gains on 5p15, Bp11-q11. 7p12, and 8q24 are rare in sputum cells of individuals at high risk of lung cancer. Lung Cancer 2006;54:169-76.
52. Venkatraman L, Catherwood MA, Patterson A, et al. Role of polymerase chain reaction and immunocytochemistry in the cytological assessment of lymphoid proliferations. J Clin Pathol 2006;59:1160-5.
53. Schmitt FC, Soares R, Cirnes L, et al. PCR amplification of DNA obtained from archived hematoxylin-eosin and Giemsa-stained breast cancer aspirates. Diagn Cytopathol 1998;19:395-7.
54. Khoury JD. Ewing sarcoma family of tumours. Adv Anat Pathol 2005;12:212-20.
55. Jakowski JD, Wakely PE Jr. Cytopathology of extraskeletal myxoid chondrosarcoma: report of 8 cases. Cancer 2007;111:298-305.
56. Schmitt FC. Thyroid cytology: FNA is still the best diagnostic approach. Cytopathology 2006;17:211-2.
57. DeLellis RA. Pathology and genetics of thyroid carcinoma. J Surg Oncol 2006;94:662-9.
58. Cheung CC, Carydis B, Ezzat S, et al. Analysis of ret/PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer. J Clin Endocrinol Metab 2001;86:2187-90.
59. Jin L, Sebo TJ, Nakamura N, et al. BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn Mol Pathol 2006;15:136-43.
60. Castro P, Rebocho AP, Soares RJ, et al. PAX8-PPARγ rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 2006;91:213-20.
61. Foukakis T, Gusnanto A, Au AY, et al. A PCR-based expression signature of malignancy in follicular thyroid tumours. Endocr Relat Cancer 2007;14:381-91.
62. Barroca H, Carvalho JL, Gil da Costa MJ, et al. Detection of N-myc amplification in neuroblastomas using southern blotting on fine needle aspirates. Acta Cytol 2001;45:169-72.
63. Krishnamurthy S. Applications of molecular techniques to fine-needle aspiration biopsy. Cancer 2007;111:106-22.
64. Schmitt FC. Cells carry the clue for targeted treatment: a new horizon for cytopathology. Cytopathology 2007;18:275-7.
65. Engel RH, Kaklamani VG. HER2-positive breast cancer: current and future treatment strategies. Drugs 2007;67:1329-41.
66. Johnston SR, Leary A. Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer. Drugs Today 2006;42:441-53.
67. Hanna WM, Kwok K. Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. Mod Pathol 2006;19:481-7.
68. Ricardo S, Milanezi F, Carvalho S, et al. HER2 evaluation through the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinoma. J Clin Pathol 2007;60:1001-5.
69. Lambros MB, Simpson PT, Jones C, et al. Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization. Lab Invest 2006;86:398-408.
70. Vocaturo A, Novelli F, Benevolo M. Chromogenic in situ hybridization to detect HER-2/neu gene amplification in histological and ThinPrep-processed breast cancer fine-needle aspirates: a sensitive and practical method in the trastuzumab era. Oncologist 2006;11:878- 86.
71. Shih JY, Gow CH, Yu CJ, et al. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer 2006;118:963-9.
72. Daniele L, Macrí L, Schena M, et al. Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens. Mol Cancer Ther 2007;6:1223-9.
73. Reis-Filho JS, Milanezi F, Carvalho S, et al. Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. Breast Cancer Res 2005;7:R1028-35.
74. Gomes AL, Bardales RH, Milanezi F, et al. Molecular analysis of c-Kit and PDGFRA in GISTs diagnosed by EUS. Am J Clin Pathol 2007;127:89-96.